Celularity Inc. (NASDAQ:CELUW) Sees Large Growth in Short Interest
Celularity Inc. (NASDAQ:CELUW) Sees Large Growth in Short Interest
Celularity Inc. (NASDAQ:CELUW – Get Rating) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 18,300 shares, a growth of 190.5% from the January 31st total of 6,300 shares. Based on an average daily volume of 14,200 shares, the short-interest ratio is currently 1.3 days.
奇魯達公司（NASDAQ：CELUW-獲取評級）在二月份的短期興趣大增長的收件人。截至 2 月 15 日，短期利息總額為 18,300 股，較 1 月 31 日的 6,300 股股份增長了 190.5%。根據每日平均成交量 14,200 股，短息比率目前為 1.3 天。
Celularity Stock Performance
卓越股票表現
Shares of Celularity stock opened at $0.08 on Wednesday. Celularity has a one year low of $0.06 and a one year high of $1.99. The firm has a 50-day moving average price of $0.09.
星期三股票以 0.08 美元開盤。天然的一年低點為 0.06 美元，一年新高為 1.99 美元。該公司的 50 天移動平均價為 0.09 美元。
Celularity Company Profile
卓達公司簡介
(Get Rating)
(取得評分)
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
Celularity Inc 是臨床階段的生物技術公司，開發現成的胎盤衍生異基因細胞療法，用於治療癌症，免疫和傳染病。它通過三個部分進行操作：細胞治療，退行性疾病和生物班王。該公司的主要治療方案包括 CYCART-19，胎盤衍生的 CAR-T 療法，該療法正在治療 B 細胞惡性腫瘤的 I 期臨床試驗中；CYNK-001，胎盤衍生的未修飾天然殺傷劑（NK）細胞，該細胞處於治療急性髓細胞白血病的 I 期臨床試驗中，以及用於治療急性髓細胞白血病的 I/IIA 期臨床試驗中，用於膠質瘤和 COVID-19 多形瘤治療試驗; CYNK-101 是一種異體轉基因 NK 細胞，正處於治療 HER2+ 胃癌和胃食管癌的 I 期臨床試驗中；APPL-001，胎盤-衍生的間充質樣附著劑基質細胞，處於治療克羅恩氏病的臨床前階段；和 PDA-002，胎盤衍生的間葉類粘附劑基質細胞，處於臨床前階段，用於治療面部異位素的肌肉營養不良。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Celularity (CELUW)
- Will Q4 Results Send Zoom Video Stock Higher?
- Is Amazon a Blue Chip Stock?
- Occidental Petroleum Pulls Back To The Sweet Spot
- Should You Take a Cruise in Royal Caribbean Stock?
- Is Target Stock Aiming For A Breakout In 2023?
- 免費獲取有關天然性研究報告的副本
- 第四季度的結果會發送縮放視頻庫存更高嗎？
- 亞馬遜是藍籌股嗎？
- 西方石油拉回甜蜜點
- 您應該乘坐皇家加勒比國際遊輪嗎？
- 目標股票是否瞄準在 2023 年突破？
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
接收每日奇魯特的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Celularity 和相關公司的最新新聞和分析師評級的簡要每日摘要。